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Several	  case	  reports	  have	  suggested	  the	  involvement	  of	  ATV	  in	  nephrolithiasis.The	  incidence	  of	  renal	  stones	  
is	  approximately	  10	  times	  higher	  among	  patients	  on	  ATV/r	  than	  those	  on	  other	  PIs.	  We	  report	  a	  case	  of	  an	  


















Atazanavir/ritonavir	   administration	   has	   been	   recently	   showed	   to	   be	   	   a	   risk	   factor	   for	   symptomatic	  
nephrolithiasis1	   .Atazanavir	  could	  promote	  kidney	  stones	  trough	  	  similar	  mechanisms	  to	  indinavir-­‐induced	  
urolithiasis	   (drug	   crystallization	   and	   precipitantion	   in	   the	   kidneys)1.de	   Lastours	   	   and	   colleagues	   showed	  	  
high	   levels	   of	   atazanavir	   and	   darunavir	   in	   urine	   with	   crystalluria	   in	   asymptomatic	   HIV-­‐infected	   patients,	  	  
being	  urinary	  atazanavir	   	  and	  darunavir	  concentrations	  significantly	  higher	  than	  plasma	  levels2.	  We	  report	  
the	  first	  	  case	  of	  an	  HIV-­‐1-­‐infected	  patient	  on	  atazanavir/ritonavir	  (300/100	  mg	  daily)	  with	  recurrent	  kidney	  
stone	  episodes,	  who	  benefit	   from	  a	  atazanavir	  dose	  reduction.	  A	  30-­‐year	  old	  man	  (CDC	  A2),	  HIV-­‐infected	  
since	   2007,	  without	   HBV	   or	   HCV	   co-­‐infections,	   came	   to	   our	   attention	   in	  October	   2012.	   The	   patient	  was	  
taking	  tenofovir/emtricitabine	  and	  atazanavir/ritonavir	  (300/100	  mg	  daily)	  since	  June	  2011(after	  four	  years	  
of	   	   fully	   suppressive	   first-­‐line	   regimen	   	   of	   tenofovir/emtricitabine	   and	  efavirenz)	  with	  optimal	   adherence	  
but	   complaining	   of	   scleral	   icterus.	   T	   CD4+	   cell	   count	   was	   903/mm3,	   HIV	   RNA	   <20	   copies/ml	   and	   total	  
bilirubin	  6.11	  mg/dl.	  Family	  history	  was	  unremarkable	  for	  urolithiasis.	  Blood	  tests	  did	  not	  show	  any	  plasma	  
lipids,	   kidney	   function	   (eGFR	   >90mL/min/1.72m2)	   and	   uric	   acid	   levels	   abnormalities.	   He	   reported	   three	  
kidney	   stones	   episodes	   in	   the	   last	   year	   (December	   2011	   ,	   May	   and	   September	   2012)	   after	   starting	  
atazanavir-­‐containing	   treatment.	   Renal	   echography	   showed	   thin	   bilateral	   stones	   (October	   2012).	   We	  
decided	  to	  reduce	  the	  dose	  of	  atazanavir	  to	  200	  mg	  daily	  with	  100	  mg	  of	  ritonavir	  to	  reduce	  his	  discomfort	  
due	   to	   atazanavir-­‐related	   jaundice,	   collecting	   paired	   plasma	   and	   urine	   samples	   for	   pharmacokinetic	  
analysis3.	   Atazanavir	   	   Ctrough	   was	   1017	   ng/ml	   	   in	   plasma	   and	   37110	   ng/ml	   in	   urine	   sample	   before	   dose	  
reduction.	  One	  month	  after	   (November	  2012),	  HIV	  RNA	  was	  still	  <	  20	  copies/ml	  and	   total	   	  bilurbin	  value	  
was	  dropped	  to	  3.30	  mg/dl.	  On	  June	  2013,	  he	  did	  not	  report	  any	  episodes	  of	  renal	  stones,	  but	  the	  patient	  
continued	   to	   report	  discomfort	   for	   the	  persistent	   scleral	   icterus.	  Atazanavir	  dose	  was	   further	   reduced	   to	  
150	  mg	  daily	  with	  100	  mg	  daily	  of	  ritonavir.	  On	  December	  2013,	  CD4	  cell	  count	  was	  660/mm3,	  HIV	  RNA	  not	  
detectable,	   and	   total	  bilurbin	  1.26	  mg/dl,	  with	  disappearance	  of	   scleral	   icterus.	  After	   thirteen	  months	  of	  
follow	   up,	   he	   no	   longer	   reported	   any	   sign	   of	   urolithiasis,	   and	   a	   renal	   echography	   did	   not	   show	   any	  
radiological	   findings	  of	  renal	  stones.	  At	  a	  second	  pharmacokinetics	  analysis,	  ATV	  Ctrough	  was	  160	  and	  4683	  
ng/ml	   in	   plasma	   and	   urine,	   respectively.Nephrolithiasis	   has	   been	   reported	   in	   patients	   receiving	   ATV/r-­‐
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containing	   antiretroviral	   therapy2,4.Several	   case	   reports	   documented	   high	   concentrations	   of	   ATV	   in	   renal	  
stones,	  suggesting	  the	  involvement	  of	  ATV	  in	  nephrolithiasis4-­‐6.	  Hamada	  et	  al	  recently	  reported	  in	  a	  single	  
center	  cohort	  study	  that	  the	  incidence	  of	  renal	  stones	  is	  approximately	  10	  times	  higher	  among	  patients	  on	  
ATV/r-­‐containing	  antiretroviral	   therapy	   (ART)	   than	   those	  on	  other	  PIs-­‐containing	  ART1.The	  mechanism	  of	  
atazanavir/ritonavir-­‐induced	  renal	  stone	  formation	  could	  be	  the	  crystallization	  of	  atazanavir,	  as	  in	  the	  case	  
of	   indinavir-­‐induced	   renal	   stones6.Although	   in	   our	   case	  ATV	   concentrations	  were	   higher	   in	   urine	   than	   in	  
plasma,	   as	   expected2,	   a	   dramatic	   decrease	   of	   urine	   concentration	   (by	   88%)	   was	   showed	   after	   dose	  
reduction	  to	  boosted	  150	  mg	  daily,	  with	  disappearance	  of	  symptoms	  and	  signs	  of	  renal	  stones.	  This	  finding	  
confirms	  the	  need	  of	  a	  threshold	  of	  ATV	  urinary	  concentration	  to	  form	  precipitation	  in	  crystals2.ATV	  plasma	  
concentrations	  are	  known	   to	   correlate	  with	   serum	  bilirubin	   level	  and	   switch	   to	  unboosted	  ATV	  has	  been	  
described	   to	   reduce	   the	   risk	   of	   hyperbilirubinemia8.Rockwood	   et	   al7	   	   found	   a	   close	   association	   between	  
hyperbilirubinemia	  and	  the	  development	  of	   renal	   stones,	   supporting	   the	  association	  of	  both	  with	  plasma	  
exposure,	   and,	   for	   the	   latter,	  with	   urinary	   exposure	   too.	   ATV	   crystalluria,	   in	   fact,	   has	   been	   shown	   to	   be	  
related	   	   to	   duration	   of	   ATV	   intake,	   but	   also	   to	   be	   more	   frequent	   in	   RTV-­‐boosted	   dose	   (300/100)	   as	  
compared	   to	   unboosted	   400	   mg	   dose	   intakers2.	   It	   is	   noteworthy	   to	   remember	   that	   even	   in	   indinavir-­‐
intakers	  dose	  reduction	  and	  TDM	  were	  effective	  in	  case	  of	  renal	  stones9.	  In	  our	  case,	  such	  unconventional	  
dose	   reduction	   allowed	   to	   continue	   ATV-­‐containing	   effective	   regimen,	   with	   a	   clear	   improvement	   of	  
tolerability,	  while	  maintaining	   virological	   efficacy.	  A	  dose	  decrease	   to	  boosted	  150	  mg/daily,	   in	   fact,	  was	  
associated	  with	  ATV	  Ctrough	  still	  above	  the	  minimum	  effective	  concentration	  (MEC	  ,150	  ng/ml).	  We	  could	  
speculate	  that	  ATV	  Ctrough	  value	  of	  our	  patient	  dosed	  at	  150	  mg	  with	  100	  mg	  of	  RTV	  was	  in	  the	  expected	  
range	  of	  unboosted	  ATV	  pharmacokinetics8,	  and	  switch	  to	  unboosted	  ATV	  has	  been	  shown	  to	  be	  effective	  
in	   stable	   patients8.	   Anyway,	   we	   recently	   reported	   the	   efficacy	   of	   a	   maintenance	   reduced	   dose	   of	  
atazanavir/ritonavir	  in	  a	  small	  cohort	  of	  virologically	  suppressed	  HIV-­‐infected	  patients10.In	  conclusion,	  ATV	  
dose	   reduction	   in	   stable	   patients	   reporting	   the	   occurrence	   of	   ATV-­‐related	   renal	   stones	   deserves	   further	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